Meeting
2016 Gastrointestinal Cancers Symposium
The minimal effective relative dose intensity (RDI) for modified FOLFIRINOX in advanced pancreatic cancer: Suggestion for modified Hryniuk’s calculation method.
Authors
Jong-chan Lee
Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
Jong-chan Lee , Kyu-hyun Paik , Hyoung Woo Kim , Jingu Kang , Young Soo Park , Jaihwan Kim , Jin-Hyeok Hwang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 402)
DOI
10.1200/jco.2016.34.4_suppl.402
Abstract #
402
Poster Bd #
K18
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO).
First Author: Fergus Keane
Poster
2018 ASCO Quality Care Symposium
Treatment patterns, toxicity, and outcomes of elderly patients with advanced pancreatic cancer receiving first-line chemotherapy.
First Author: Robert Kudlovich
Poster
2015 Gastrointestinal Cancers Symposium
Investigation of the tolerability of FOLFIRINOX in patients with unresectable advanced pancreatic cancer: Single-institution experience in Japan.
First Author: Kouichirou Miyashita
Poster
2020 ASCO Virtual Scientific Program
Pharmacokinetically-guided 5-FU dose optimization within the preoperative FOLFOXIRI regimen in resectable pancreatic cancer patients.
First Author: Anna Vilalta